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Abstract
Background Emergency treatment of bleeding esophageal varices in cirrhosis is of singular importance because of the high
mortality rate. Emergency portacaval shunt is rarely used today because of the belief, unsubstantiated by long-term randomized
trials, that it causes frequent portal-systemic encephalopathy and liver failure. Consequently, portacaval shunt has been relegated
solely to salvage therapy when endoscopic and pharmacologic therapies have failed. Question: Is the regimen of endoscopic
sclerotherapy with rescue portacaval shunt for failure to control bleeding varices superior to emergency portacaval shunt? A
unique opportunity to answer this question was provided by a randomized controlled trial of endoscopic sclerotherapy versus
emergency portacaval shunt conducted from 1988 to 2005.
Methods Unselected consecutive cirrhotic patients with acute bleeding esophageal varices were randomized to endoscopic
sclerotherapy (n=106) or emergency portacaval shunt (n=105). Diagnostic workup was completed and treatment was
initiated within 8 h. Failure of endoscopic sclerotherapy was defined by strict criteria and treated by rescue portacaval shunt
(n=50) whenever possible. Ninety-six percent of patients had more than 10 years of follow-up or until death.
Results Comparison of emergency portacaval shunt and endoscopic sclerotherapy followed by rescue portacaval shunt
showed the following differences in measurements of outcomes: (1) survival after 5 years (72% versus 22%), 10 years (46%
versus 16%), and 15 years (46% versus 0%); (2) median post-shunt survival (6.18 versus 1.99 years); (3) mean requirements
of packed red blood cell units (17.85 versus 27.80); (4) incidence of recurrent portal-systemic encephalopathy (15% versus
43%); (5) 5-year change in Child’s class showing improvement (59% versus 19%) or worsening (8% versus 44%); (6) mean
quality of life points in which lower is better (13.89 versus 27.89); and (7) mean cost of care per year ($39,200 versus
$216,700). These differences were highly significant in favor of emergency portacaval shunt (all p<0.001).
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DOI 10.1007/s11605-010-1279-7Conclusions Emergency portacaval shunt was strikingly superior to endoscopic sclerotherapy as well as to the
combination of endoscopic sclerotherapy and rescue portacaval shunt in regard to all outcome measures, specifically
bleeding control, survival, incidence of portal-systemic encephalopathy, improvement in liver function, quality of life,
and cost of care. These results strongly support the use of emergency portacaval shunt as the first line of emergency
treatment of bleeding esophageal varices in cirrhosis.
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Abbreviations
BEV Bleeding esophageal varices
EST Endoscopic sclerotherapy
EPCS Emergency portacaval shunt
PCS Portacaval shunt
UGI Upper gastrointestinal
ICU Intensive care unit
PRBC Packed red blood cells
PSE Portal-systemic encephalopathy
EVL Endoscopic variceal ligation
QOL Quality of life
Introduction
Emergency treatment of bleeding esophageal varices (BEV)
in patients with cirrhosis of the liver is of singular
importance because of the high mortality rate surrounding
the episode of acute bleeding.
1–9 The most widely used
emergency treatment of BEV is endoscopic sclerotherapy
(EST) or endoscopic variceal ligation (EVL), with or
without the addition of pharmacologic measures.
10–12
When it is believed that portal decompression is needed,
transjugular intrahepatic portosystemic shunt (TIPS) has
become the most widely used procedure of choice despite
the facts that, as we have pointed out previously, TIPS has a
high rate of stenosis and occlusion, a resultant high
incidence of portal-systemic encephalopathy (PSE), and
limited durability. TIPS occlusion rate has been reduced by
the recent introduction of the polytetrafluorethylene-coated
stent, but the rates of occlusion and PSE are still much
higher than the incidences of these serious complications
following portacaval shunt in all of our studies.
Emergency portacaval shunt (EPCS) is rarely used
today because of the belief, unsubstantiated by random-
ized controlled trials involving unselected patients, that
EPCS causes frequent portal-systemic encephalopathy
and liver failure.
4,13–21 Consequently, portacaval shunt
(PCS) has been relegated solely to the salvage of failed
endoscopic and pharmacologic treatment. An important
question is: is the regimen of EST or ligation with rescue
PCS for failure to control BEV superior to EPCS? A unique
opportunity to compare the regimen of EST with rescue PCS
with EPCS was provided by our randomized controlled trial
(RCT) of EST versus EPCS known as the San Diego
Bleeding Esophageal Varices Study.
From April 8, 1988 to December 31, 2005, we
conducted a RCT in 211 unselected, consecutive patients
with cirrhosis and acute BEV in whom emergency and
long-term EST was compared with direct EPCS, otherwise
known as total shunt. The trial was a community-wide
endeavor that involved patients referred from four adjacent
counties to the University of California, San Diego (UCSD)
Medical Center. In two recent publications, we described
the study in detail and reported the outcomes first with
regard to control of bleeding and survival
22 and second
with regard to the development of PSE.
23 This report
focuses on a comparison of outcomes following the
regimen of EST with rescue PCS to outcomes following
EPCS.
Patients and Methods
The reader is directed to our two recent publications
22,23
that provide detailed descriptions of the following methods
and protocols used in this RCT:
1. Design of study
24,25
2. Patient eligibility
3. Definitions of:
(a) Bleeding esophageal varices
(b) Unselected patients (all comers)
(c) Emergency EST
(d) Long-term EST
(e) Emergency portacaval shunt
(f) Failure of emergency primary therapy
(g) Failure of long-term therapy
(h) Rescue therapy
(i) Informed consent
4. Randomization
5. Diagnostic workup
26
6. Quantitative Child’s classification
27,28
7. Initial emergency therapy during workup
8. Endoscopic sclerotherapy
9. Emergency portacaval shunt
29
10. Lifelong follow-up
11. Quantitation of PSE
In addition, the RCT involved the following protocols
that have not been described previously.
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Rescue PCS was performed in 50 patients as soon as possible
after failure of EST was declared. Direct side-to-side PCS was
donein46patients(92%),anddirectend-to-side PCSwasdone
in four patients (8%). Operative technique and intraoperative
pressure measurements were identical to those used in EPCS.
QOL Score
Quality of life (QOL) was measured by assessing the
following factors: (1) liver function as determined by
quantitative Child’s risk class; (2) development of recurrent
PSE; (3) number of PSE episodes; (4) units of packed red
blood cell (PRBC) transfusion for upper gastrointestinal
bleeding; (5) number of hospital readmissions; (6) days of
hospitalization during readmission; (7) return to work,
including housekeeping; (8) abstinence from alcoholism;
and (9) portacaval shunt patency. These nine factors were
weighted numerically so as to produce a QOL score in which
the lower the score, the better the QOL.
Direct Cost of Care
All hospital and outpatient facility charges and all profes-
sional fee bills from UCSD and from referring hospitals and
physicians were obtained continuously for every patient
entered into the study for 10 years.
Figure 1 is a Consort flow diagram that shows the
overall design and conduct of the RCT.
22,23
Statistical Analysis
The comparison between Emergency and Rescue PCS groups
used Fisher’s exact test for binary outcomes (e.g., control of
bleeding, incidence of recurrent PSE) and Wilcoxon rank-sum
test (WRT) for continuous outcomes (e.g., units of PRBC
transfusion, number of recurrent PSE episodes, number of
hospital readmissions). The length of survival was compared
using Gehan–Wilcoxon rank test. The change in Child’sc l a s s
was compared for each time interval using the exact WRT,
adjusted for ties. The average change in Child’s class during the
first 5 years was computed by averaging the duration of time in
years spent by the patients at risk (alive) in each category
(improved, unchanged, or worse). The comparison of the cause
of recurrent PSE episodes used Pearson’s chi-squared test. The
overall quality of life score was computed for each group and
each year by adding up the scores of the nine components. This
score was compared between the two groups assuming a
Poisson (log-linear) model, with different means for the
different categories, and a constant group effect. At the
beginning of the study, it was decided in advance not to
perform an interim analysis of the data.
Results
EPCS Versus EST—Outcome Data
Our recent publications should be consulted for detailed data
on the clinical characteristics of the 211 patients, findings on
upper endoscopy and liver biopsy, results of laboratory blood
tests, data on rapidity of therapy, data on control of bleeding,
operative and endoscopic data, data on PSE, and data on
survival.
22,23 There were no significant differences in the
clinical characteristics of the two groups on entry in the RCT.
Cirrhosis was demonstrated by liver biopsy in all patients.
Definitive treatment was initiated in <24 h after onset of
bleeding in all patients. EPCS controlled bleeding perma-
nently in all patients, while EST achieved permanent control
of bleeding in only 20%. Survival rates were significantly
higher after EPCS than after EST at all time intervals and in
all Child’sc l a s s e s( p<0.001). Patients with the most severe
liver disease in Child’s risk class C realized substantial long-
term survival after EPCS.
The incidence of recurrent PSE following EST was 35%,
which was more than twice the 15% incidence following
EPCS (p<0.001). EST patients had a total of 179 episodes
of PSE and 146 PSE-related hospital admissions compared
with EPCS patients who had 94 episodes of PSE and 87
hospital admissions (p=0.003). Recurrent UGI bleeding,
which was rare in the EPCS group, was a major causative
factor of PSE in the EST patients.
EST with Rescue PCS Versus EPCS
Patient Characteristics
Table 1 summarizes the clinical characteristics at the time of
entry in the San Diego BEV study of the 105 patients who
were randomized to EPCS and the 50 patients who failed
EST and underwent rescue PCS. There were no significant
differences between the two groups in any important
characteristics of cirrhosis and BEV. Thirty-one patients
failed EST but did not undergo rescue PCS for various
reasons, most prominent of which were death from recurrent
BEVat home or at a distant hospital and death from massive
recurrence of BEV before a rescue PCS could be done. As
others have found, failure of patients to take advantage of
rescue treatment reflects the realities of treating BEV in the
cirrhotic population. Although these 31 patients were
excluded from the analysis, their deaths have a negative
impact on the concept of rescue PCS for failed EST.
Table 2 summarizes data on rapidity of therapy and
indicates clearly that all patients underwent rapid
diagnosis and treatment upon entry in the RCT. Median
timefromonsetofbleedingtothestartoftherapywas<24hin
bothgroupsofpatients.ThetimefrominitialcontactatUCSD
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the EST group and in 102 of the 105 patients in the EPCS
gr ou p.Ac ti vebl ee di ngwa sob se rv edw it hi n4hofen tr yinth e
study in 83% of the 155 patients.
Control of Bleeding
Table 3 provides data on control of BEV by EPCS and
by EST with rescue PCS. EPCS promptly and perma-
nently controlled bleeding in every patient. In contrast,
EST failed to control bleeding in any of the 50 patients,
and that is why they underwent rescue PCS. Failure of
EST in 106 patients in the EST group was based on one
or more of the criteria established in advance by the
study protocol, which included: (1) in 15 patients,
variceal bleeding continued or recurred during the first
7 days after initial EST and required ≥6 U blood
transfusion; (2) in 47 patients, recurrent variceal bleeding
required ≥8 U of blood transfusion during any 12-month
period after the index hospitalization; (3) in 27 patients,
variceal bleeding recurred after an experienced
co-investigator faculty gastroenterologist had previously
declared that the esophageal varices were obliterated or
gone. In eight of these same patients, recurrent bleeding
required ≥8 U of blood transfusion, so they met two
criteria of failure.
Table 3 also summarizes the requirement for PRBC
transfusions. Overall, patients treated by EST with
rescue PCS required almost twice the number of PRBC
transfusions as patients treated by primary EPCS
(p<0.001).
Survival
Table 4 shows data on survival in the two groups of
patients, and Fig. 2 shows 15-year Kaplan–Meier estimated
survival plots. All patients in the EST-rescue PCS group and
98 of the 105 patients in the EPCS group were eligible for ten
or more years of follow-up. The remaining seven EPCS
patientshadfollow-upfor9.4–9.9 years. No patients were lost
to follow-up. After the first year, there were highly significant
differences in the survival rates of the two study groups at all
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with Rescue PCS
Primary EPCS (n=105) Rescue PCS (n=50) p value
History
Age (years)
Mean/median 49.9/47 47.7/44.5 0.27
Range 28–82 30–75
Male gender, n (%) 81 (78) 39 (78) 1.0
Race, n (%) 0.43
Caucasian 58 (55) 23 (46)
Hispanic 39 (37) 24 (48)
Other 8 (8) 3 (6)
Cause of cirrhosis, n (%) 0.93
Alcoholism alone 54 (51) 27 (54)
Hepatitis B or C alone 8 (8) 4 (8)
Alcoholism and hepatitis 33 (31) 16 (32)
Other 10 (10) 3 (6)
Chronic alcoholism, n (%) 87 (83) 43 (86) 0.82
Years of alcoholism median/range 25/7–54 24/5–59 0.69
Recent alcohol ingestion ≤7 days, n (%) 74 (70) 33 (66) 0.58
Past history, n (%)
Jaundice 58 (55) 27 (54) 1.00
Ascites 48 (46) 31 (62) 0.062
Portal-systemic encephalopathy 30 (29) 7 (14) 0.069
Physical examination, n (%)
Jaundice 38 (36) 19 (38) 0.86
Ascites 54 (51) 30 (60) 0.39
Portal-systemic encephalopathy 19 (18) 8 (16) 0.82
Severe muscle wasting (2+ or 3+ on 0–3+ scale) 67 (64) 25 (50) 0.12
PSE index
Median (interquartile range) 0 (0–0.15) 0 (0–0.9) 0.066
Child’s risk class, n (%) 0.58
A( 5 –8 points) 26 (25) 14 (28)
B( 9 –11 points) 49 (47) 26 (52)
C (12–15 points) 30 (29) 10 (20)
Child’s risk class points
Mean/median 10.0/10 9.8/9 0.37
Liver biopsy—cirrhosis
n (%) 105 (100) 50 (100) 1.0
Findings on endoscopy, n (%)
Esophageal varices 105 (100) 50 (100) 1.0
Size 2 + to 4 + (on scale of 0–4+) 105 (100) 49 (98) 0.85
Active bleeding 29 (28) 24 (48) 0.018
a
Clot on varices 51 (49) 25 (50) 1.0
Red color signs on varices 66 (63) 29 (58) 0.60
Gastric varices on endoscopy 17 (16) 10 (20) 0.65
Portal hypertensive gastropathy 22 (21) 12 (24) 0.68
Gastritis/erosions 14 (13) 7 (14) 1.0
Reason for not undergoing rescue PCS, n (%)
BEV and death elsewhere, not at UCSD 13 (42)
Massive recurrent BEV and death 11 (35)
1786 J Gastrointest Surg (2010) 14:1782–1795long-term time intervals. The 5-, 10-, and 15-year
survival rates in the EST-rescue PCS group were 22%,
16%, and 0%, respectively, and in the EPCS group were
72%, 46%, and 46%, respectively (p<0.001). Median
survival was 6.15 years in patients randomized to EPCS
compared to 3.1 years in EST-rescue PCS patients (p<
0.001). Hepatic failure was the primary cause of death in
44% of patients who underwent EST with rescue PCS
compared to 22% of patients who received primary EPCS.
In contrast to the entire group of 106 EST patients in
which 26% died from variceal bleeding, none of the 105
EPCS patients died of bleeding.
As expected, the survival rate was related to the severity of
liver disease at the time of entry in the study, as expressed by
quantitative Child’s risk classes. In the EST group with rescue
PCS, 5-year survival rates in Child’s classes A, B, and C were
36%, 15%, and 20%, respectively, and 10-year survival rates
in Child’s classes A, B, and C were 29%, 12%, and 10%,
respectively. In contrast, in the EPCS group, the
corresponding survival rates in Child’s classes A, B, and C
were 89%, 76%, and 53% at 5 years and 62%, 47%, and 30%
at 10 years. The differences in favor of EPCS were highly
significant (p=0.005 to p<0.001).
Median survival of patients who failed EST and
underwent a rescue PCS was 3.01 years compared to
median survival of 2.36 years in the 38% of patients who
failed EST but did not undergo a rescue PCS. Importantly,
median postoperative survival following rescue PCS was
only 1.99 years compared to 6.18 years following primary
EPCS (p<0.001).
Portal Systemic Encephalopathy
Table 5 shows data on PSE in the two groups of patients.
Calculations of the incidence of PSE are based on patients
who were discharged from the index hospitalization and
survived more than 30 days after study entry since deaths
on or before 30 days were considered indeterminate and
unrelated to PSE. As we have reported previously, the
incidence of PSE was 35% in the primary EST group and
15% in the primary EPCS group (p=0.001).
23 The
difference in incidence of PSE was even greater when the
primary EPCS group with its 15% PSE incidence was
compared to the EST-rescue PCS group in which the PSE
incidence was 43% (p<0.001). Furthermore, as shown in
Table 5, the number of episodes of PSE per patient and per
Table 2 Rapidity of Therapy of Patients with Cirrhosis and Bleeding Esophageal Varices Randomized to EPCS or EST followed by Rescue PCS
Hours Primary EPCS (n=105) EST then Rescue PCS (n=50) p value
Median/mean Range Median/Mean Range
Onset bleeding to study entry 16/19.5 0–95 10/17.5 0–144 0.038
a
Onset bleeding to primary therapy 19/24.0 2.6–100.3 13.4/21.6 3–146.5 0.010
a
Study entry to primary therapy 3.4/4.4 1.4–24.3 2.5/3.1 1.0–7.8 <0.001
a
>8 h, n (%) 3 (2.9) 0 (0)
Transfer patients, n (%) 80 (76) 33 (66) 0.61
Onset bleeding to entry in referring hospital 3.8/9.9 0–83.6 4.5/11.2 0–127.4 0.76
Entry in referring hospital to study entry 8.4/11.6 0–53 7/11.3 1.5–43 0.33
Last observation of bleeding to study entry 0/3.1 0–30 0/3.4 0–32 0.95
≤4h , n (%) 88 (84) 41 (82)
>4 h, n (%) 17 (16) 9 (18) 0.82
EST endoscopic sclerotherapy, EPCS emergency portacaval shunt, PCS portacaval shunt
aStatistically significant difference
Table 1 (continued)
Primary EPCS (n=105) Rescue PCS (n=50) p value
Refused rescue PCS 2 (6)
Died in hepatic coma with liver failure 2 (6)
Liver transplantation 2 (6)
Perforated esophagus with sepsis 1(3)
EPCS emergency portacaval shunt, PCS portacaval shunt, PSE portal-systemic encephalopathy, BEV bleeding esophageal varices
aStatistically significant difference
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and per year were all significantly more frequent in the
EST-rescue PCS group than in the EPCS group (p<0.001).
Additionally, the EST-rescue PCS patients with PSE had a
median survival from the time of study entry of 3.44 years,
which was longer than the 2.45 years of survival of the
patients free of PSE, but the difference was not significant.
In contrast, the patients in the primary EPCS group had a
significantly longer survival than those in the EST-rescue
PCS group (p<0.001), and their median survival was
5.18 years for those with PSE and 10.43 years in those
free of PSE (p<0.001).
Dietary indiscretion with regard to protein restriction
was the most frequent cause of recurrent PSE in both
groups of patients. Portal hypertension-related UGI
bleeding, usually from BEV, was the main cause of
PSE in 23% of the episodes of PSE in the EST-rescue
PCS group and was a contributing cause in an additional
16%. PSE episodes occurred more frequently prior to
performance of rescue PCS than after rescue PCS. UGI
bleeding was infrequently responsible for PSE in patients
randomized to EPCS, occurring in only 8% of the
patients even though they survived more than twice as
long as the EST-rescue PCS patients (p<0.001).
Table 3 Control of Bleeding in Patients with Cirrhosis and Bleeding Esophageal Varices Randomized to EPCS or EST followed by Rescue PCS
Primary EPCS (n=105) Primary EST then Rescue PCS (n=50) p value
Success of primary therapy, n (%)
Indeterminate—non-bleeding death ≤14 days 11 (10) 0 (0) 0.017
a
Indeterminate—non-bleeding death ≤30 days 15 (14) 2 (4) 0.060
Successful control by primary therapy
Excluding indeterminates for at least 14 days 94 (100) 0 (0) <0.001
a
Excluding indeterminates for at least 30 days 90 (100) 0 (0) <0.001
a
>30 days 89 (100) 0 (0) <0.001
a
Reason in EST group for declaration of primary
therapy failure, n (%)
Required ≥6 U PRBC in first 7 days – 15 (19)
Required ≥8 U PRBC in any 12 months – 47 (58)
Recurrent variceal bleeding after variceal
obliteration was declared
– 27 (34)
More than one criterion for failure – 8 (10)
Successful control of bleeding by rescue PCS
n (%) – 50 (100)
PRBC transfusion—units PRBC, mean/median (range)
Index hospitalization
Before primary treatment 5.78/5 (2–17) 4.48/4 (2–10) 0.005
a
During primary treatment 6.31/3 (0–68) 0.62/0 (0–6) <0.001
a
Catch-up after primary treatment 1.17/0 (0–21) 0.26/0 (0–4) 0.14
Post-therapy bleeding
Variceal 0/0 (0–0) 6.92/2 (0–35) <0.001
a
Non-variceal 1.75/0 (0–29) 0.38/0 (0–5) 0.30
Total PRBC units 14.99/10 (2–81) 12.66/7 (2–44) 0.16
Readmission for bleeding
Variceal bleeding 0.36/0 (0–26) 10.58/9 (0–60) <0.001
a
Non-variceal bleeding 3.45/0 (0–33) 5.19/0 (0–36) 0.93
Total PRBC units 3.81/0 (0–33) 15.77/10 (0–60) <0.001
a
Grand total PRBC units
Variceal bleeding 13.56/10 (2–73) 22.44/19 (7–64) <0.001
a
Variceal and non-variceal bleeding 17.83/14 (2–81) 27.80/23 (7–64) <0.001
a
EPCS emergency portacaval shunt, EST endoscopic sclerotherapy, PCS portacaval shunt, U units, PRBC packed red blood cells
aStatistically significant difference
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Survival data Primary EPCS (n=105) Primary EST then Rescue PCS (n=50) p value
Overall survival—Pr (95% CI)
30 days 0.86 (0.79–0.93) 0.96 (0.91–1.00) 0.073
1 year 0.80 (0.73–0.88) 0.80 (0.70–0.92) 1.0
5 years 0.72 (0.64–0.82) 0.22 (0.13–0.37) <0.001
a
10 years 0.46 (0.37–0.56) 0.16 (0.08–0.30) <0.001
a
15 years 0.36 (0.27–0.47) NA (NA, NA)
Median survival, years (95% CI) 6.15 (5.58–10.43) 3.00 (1.51–4.33) <0.001
a
Hazard ratio of death (95% CI) 1 2.24 (1.50–3.35)
Survival by Child’s risk class—Pr (95% CI)
5 years
Class A, n (26 EPCS, 14 rescue) 0.89 (0.77–1.00) 0.36 (0.18–0.72) 0.001
a
Class B, n (49 EPCS, 26 rescue) 0.76 (0.64–0.89) 0.15 (0.06–0.38) <0.001
a
Class C, n (30 EPCS, 10 rescue) 0.53 (0.38–0.75) 0.20 (0.06–0.69) 0.058
10 years
Class A 0.62 (0.45–0.83) 0.29 (0.13–0.65) 0.010
a
Class B 0.47 (0.35–0.63) 0.12 (0.04–0.33) 0.005
a
Class C 0.30 (0.17–0.52) 0.10 (0.02–0.64) 0.29
Median survival—years (95% CI)
Class A 10.43 (5.58 to >10.68) 4.33 (1.46, >10.82) 0.031
a
Class B 6.24 (5.44 to >11.02) 2.71 (1.48–4.51) <0.001
a
Class C 5.17 (0.04 to 10.16) 1.37 (0.12 to >11.72) 0.35
Postoperative survival years—Pr (95% CI) 6.18 (5.61, 10.38) 1.99 (1.34–3.73) <0.001
a
EPCS emergency portacaval shunt, EST endoscopic sclerotherapy, PCS portacaval shunt, Pr probability, CI confidence interval
aStatistically significant difference
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Fig. 2 Kaplan–Meier estimates
of overall survival after emer-
gency portacaval shunt (EPCS,
n=105) and after failed endo-
scopic sclerotherapy (EST) with
rescue portacaval shunt (PCS,
n=50).
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Improvement or worsening of liver function was determined by
serial quantitative measurements of Child’s risk class monthly
during the first year after study entry and every 3 months
thereafter. An increase or decrease in two or more Child’sc l a s s
points reflected, respectively, improvement or worsening of
liver function. Table 6 presents a summary of yearly changes
in Child’s risk class using Child’s class on study entry as a
baseline and combining Child’s classes A, B, and C. Results
in patients randomized to EPCS are compared to results in the
EST-rescue PCS patients. In every year, there was a
statistically significant difference between the EPCS group
and the EST-rescue PCS group, with the patients randomized
to EPCS having more improvement and less worsening of
liver function than the patients in the EST-rescue PCS group
Table 5 Recurrent Portal-Systemic Encephalopathy in Patients with Cirrhosis and Bleeding Esophageal Varices Randomized to EPCS or EST
Followed by Rescue PCS
PSE data Primary PCS (n=88) Primary EST then rescue PCS (n=47) p value
Incidence of recurrent PSE, n (%) 13 (15) 20 (43) <0.001
a
Length of survival <0.001
a
Total days 269,927 69,060
Total years 739.0 189.1
Total days/patient 3,067.4 1,469.4
Total years/patient 8.40 4.02
Recurrent PSE episodes <0.001
a
Total episodes, n 94 118
Episodes/patient 1.07 2.51
Episodes/year of follow-up 0.13 0.62
Interval between episodes (in years) 7.86 1.60
Hospital readmissions for recurrent PSE 0.001
a
Total readmissions, n 87 91
Readmissions/patient 0.99 1.94
Readmissions/year of follow-up 0.12 0.48
Interval between episodes (years) 8.49 2.08
Cause of recurrent PSE episodes, n (%) <0.001
a
Dietary protein indiscretion 60 (61) 61 (50)
UGI bleeding 8 (8) 28 (23)
Infection 12 (12) 4 (3)
Alcoholism 4 (4) 22 (18)
Uncontrolled diabetes 11 (11) 2 (2)
Hepatic failure 0 (0) 3 (2)
Other 3 (3) 2 (2)
Relationship of PSE to survival
Median (95% CI, in years)
Patients with recurrent PSE
Overall survival 5.18 (1.26, Inf) 3.44 (1.81–7.04)
Survival after first PSE 4.15 (1.17, Inf) 2.01 (1.08–4.54)
Patients free of recurrent PSE
Overall survival 10.43 (6.24, Inf) 2.45 (1.46–4.42)
p value (recurrent versus no PSE) <0.001
a 0.62
High PSE index, n (%)
Patients with PSE index ≥0.33 12 (14) 10 (22) 0.23
Patients with PSE index ≥0.33 who had recurrent PSE clinically 4 (33) 10 (100) 0.002
a
PSE portal-systemic encephalopathy, EPCS emergency portacaval shunt, PCS portacaval shunt, UGI upper gastrointestinal, CI confidence interval
aStatistically significant difference
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in Child’s classes comparing EPCS versus EST-rescue PCS,
respectively, showed improvement in 59% versus 32% and
w o r s e n i n gi n1 0 %v e r s u s3 3 %( p<0.001). The differences in
liver function between the EPCS and EST-rescue PCS groups
were particularly striking in Child’s class C where improve-
ment in liver function was most important. Fiveyears after
entry in the RCT, liver function had improved in 94% of the
EPCS group compared to 65% in the EST-rescue PCS group,
and liver function had worsened in 4% of the EPCS group
compared to 30% of the EST-rescue PCS group. The
difference in favor of EPCS was significant (p<0.001).
Quality of Life Score
Table 7 summarizes data on QOL for 5 years in the 105
patients randomized to EPCS and the 50 patients who
failed EST and underwent rescue PCS. QOL score was
based on nine criteria shown at the bottom of Table 8.I n
the comparison, a lower score indicates a better QOL.
Overall, during each year and for the entire 5-year period
of study, QOL was significantly better, i.e., the QOL score
was lower in the EPCS group than in the EST-rescue PCS
group (p<0.001).
Direct Costs of Care
Table 8 summarizes the total charges over a 10-year period
for hospitalization and outpatient care in thousands of US
dollars in patients randomized to EPCS and those randomized
to EST-rescue PCS. The mean grand total charges over the
entire length of the study were $150,400 in the EPCS patients
and $263,600 in the EST-rescue PCS patients, a highly
significant difference (p<0.001). More importantly, the mean
grand total charges per year amounted to $39,200 in the
EPCS patients and $216,700 in the EST-rescue PCS patients,
5.5 times greater (p<0.001).
Discussion
Comment is warranted regarding the use of EST rather than
EVL in this RCT. In 1988 when the San Diego BEV Study
was initiated, EST was a mainstay of therapy of BEV and
Table 6 Changes in Child’s Class Compared to Child’s Class on Study Entry in Patients with Cirrhosis and Bleeding Esophageal Varices
Randomized to EPCS or EST Followed by Rescue PCS
Years after study entry Changes in Child’s classes—A, B, and C combined Primary EPCS Primary EST, then rescue PCS p value
1 n 89 45 0.008
a
Improved, n (%) 53 (60) 17 (38)
Unchanged, n (%) 26 (29) 16 (36)
Worse, n (%) 10 (11) 12 (27)
2 n 82 39 <0.001
a
Improved, n (%) 50 (61) 12 (31)
Unchanged, n (%) 24 (29) 14 (36)
Worse, n (%) 8 (10) 13 (33)
3 n 77 28 0.054
Improved, n (%) 44 (65) 11 (57)
Unchanged, n (%) 25 (27) 10 (32)
Worse, n (%) 8 (8) 7 (10)
4 n 75 24 <0.001
a
Improved, n (%) 45 (60) 6 (25)
Unchanged, n (%) 24 (32) 7 (29)
Worse, n (%) 6 (8) 11 (46)
5 n 76 16 <0.001
a
Improved, n (%) 45 (59) 3 (19)
Unchanged, n (%) 25 (33) 6 (38)
Worse, n (%) 6 (8) 7 (44)
1–5-year average n 89 45 <0.001
a
Improved (%) 59 32
Unchanged (%) 31 35
Worse (%) 10 33
EPCS emergency portacaval shunt, PCS portacaval shunt
aStatistically significant difference. Changes indicate an increase or decrease of two or more Child’s class points
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introduced generally, as well as at our institution, we were
well into our RCT and our investigators and senior advisors
made the unanimous decision not to change from EST to
EVL. That decision has received strong support from
studies published in 2003, 2005, and 2006 that have
questioned replacement of EST by EVL. In a survey
reported in 2003 of 93 gastroenterologists who treated
725 patients with BEV, EST was used more frequently than
EVL for control of BEVand as frequently as EVL for initial
control of acute bleeding.
11 Trials published in 2005 and
1999 reported a significantly higher failure rate with band
ligation of actively bleeding varices and an overall higher
recurrence rate of varices treated by EVL.
12,30 Moreover,
EST has been reported to be more cost-effective if active
variceal hemorrhage is present at the index endoscopy
procedure, as was the case in our RCT.
30 It is noteworthy
that none of nine randomized clinical trials summarized in
2005 observed a statistically significant difference in
survival rate between EVL and EST.
12 In a meta-analysis
of emergency EST in 40 trials involving 4031 patients
reported by Triantos et al.
10 in 2006, there was no
statistically significant difference in survival rate between
EVL and EST. The authors concluded that “the conclusive
evidence for substituting banding ligation or the combina-
tion of vasoconstrictors with sclerotherapy as better
therapeutic approaches has not been provided in
randomized trials. Sclerotherapy can remain a gold standard
in variceal bleeding….”
It is widely agreed that portal-systemic shunts are very
effective in controlling BEV. The results of our RCT
confirm such effectiveness since both EPCS and rescue
PCS promptly and permanently controlled BEV in every
patient. Nevertheless, according to numerous statements in
the literature, surgical shunts control bleeding at the
expense of an unacceptably high rate of PSE as well as
progressive liver failure, and that is the main reason why
portal-systemic shunts have been relegated to a secondary
salvage role for use solely as a last resort when endoscopic
and pharmacologic measures have failed.
4,13–21 The results
of our RCT, which involved unselected, consecutive
cirrhotic patients with all degrees of liver dysfunction,
including patients in Child’s class C, contradict the widely
held beliefs about the appropriate role of portal-systemic
shunts. According to our findings which have been reported
in detail recently,
23 the incidence of PSE following EPCS
was significantly lower (15%) than the incidence following
primary EST (35%) or after EST with rescue PCS (43%).
The protocol of our RCT describes the requirements for
achieving a low incidence of PSE.
23 These are: (1)
diagnosis and EPCS within 24 h of onset of BEV; (2)
operation by surgeons experienced in portal hypertension
Table 7 Quality of Life Score Based on Nine Criteria in Survivors Who Were Discharged from the Index Hospitalization After Undergoing
EPCS or EST Followed by Rescue PCS (Lower Score is Better QOL)
Years after study entry QOL score Primary EPCS Primary EST, then rescue EPCS p value
1 Number of patients 75–105 40–49 <0.001
a
Total points 1810 2002
Mean points 20.73 45.62
2 Number of patients 71–97 29–43 <0.001
a
Total points 1279 1004
Mean points 15.51 27.72
3 Number of patients 69–88 26–32 <0.001
a
Total points 1034 473
Mean points 13.18 16.96
4 Number of patients 67–83 19–29 <0.001
a
Total points 774 403
Mean points 10.08 17.35
5 Number of patients 66–80 11–22 <0.001
a
Total points 666 212
Mean points 8.81 13.63
0–5 Number of patients 348–453 125–175 <0.001
a
Total points 5,563 4,094
Mean points 13.89 27.89
EPCS emergency portacaval shunt, EST endoscopic sclerotherapy, PCS portacaval shunt, QOL quality of life
QOL Criteria: (1) Change in Child’s class; (2) recurrent PSE; (3) no. of PSE episodes; (4) PRBC units; (5) no. of readmissions; (6) readmission
days; (7) alcoholism; (8) return to work; (9) PCS patency
aStatistically significant difference
1792 J Gastrointest Surg (2010) 14:1782–1795surgery; (3) postoperative care in an ICU by trained and
experienced nurses and physicians; and (4) regular, long-
term follow-up that includes concerted efforts to promote
abstinence from alcohol and repeated emphasis on
reasonable restriction of dietary protein intake. It is our
conviction that these requirements can be fulfilled by
most trained surgeons and by most general hospitals in
the USA.
Regarding the matter of post-shunt liver failure, the
concept that direct portacaval shunts cause liver failure
because of diversion of essential portal blood flow began
over a century ago with the animal experiments of Eck and
Hahn and associates in Pavlov’s laboratory
31,32 and has
been suggested repeatedly but not substantiated since
then.
33–35 The concept has led to the invention of a number
of operations that are purported to maintain portal blood
flow to the liver while overcoming portal hypertension.
These include distal splenorenal shunt, small-diameter
prosthetic, H-graft portacaval shunt, and small-diameter
direct side-to-side portacaval shunt. However, the concept
is contradicted by two important hemodynamic facts. The
first is that whether or not a PCS is constructed, BEV arise
as a consequence of progressive diversion of a substantial
portion of venous blood flow away from the liver and into
portal-systemic collaterals so that, with regard to creation of
a PCS, the cirrhotic liver with BEV is markedly different
from the normal liver. The second important hemodynamic
fact is that a fundamental physiologic response to diversion
of portal venous flow is a compensatory increase in hepatic
arterial blood flow to the liver.
36–38 It is not possible by any
currently available practical method to predict the adequacy
of hepatic arterial compensation prior to performance of a
Table 8 Total Facility and Professional Fee Charges for Patients with Cirrhosis and Bleeding Esophageal Varices Randomized to EPCS or EST
Followed by Rescue PCS
Total charges and charges per day or per year in $1,000 Primary EPCS Primary EST, then Rescue PCS p value
n Mean and (SD) Range n Mean and (SD) Range
Index admission 105 50
1. Total hospital charges 69.1 (56.1) 23.1–352.6 67.6 (65.6) 7.5–433.9 0.34
Hospital charges per day 5.60 (5.85) 1.98–52.06 4.19 (2.62) 0.83–16.98 0.024
a
2. Total physician charges 11.1 (5.4) 3.3–34.8 9.1 (8.6) 1.6–50.4 <0.001
a
Physician charges per day 1.05 (1.21) 0.16–7.28 0.61 (0.48) 0.18–3.15 <0.001
a
3. Total overall charges 80.2 (60.0) 33.7–380.5 76.7 (70.9) 9.4–458.5 0.20
Overall charges per day 6.65 (6.83) 2.41–58.11 4.80 (2.81) 1.04–17.70 0.009
a
Readmission post-index 88 47
1. Total hospital charges 56.6 (71.3) 0–262.0 150.2 (183.9) 0–911.4 <0.001
a
Hospital charges per year 20.4 (48.2) 0–262.3 124.6 (273.4) 0–1642.0 <0.001
a
2. Total physician charges 8.6 (10.5) 0–49.2 19.7 (18.8) 0–89.0 <0.001
a
Physician charges per year 2.6 (5.6) 0–35.8 17.0 (35.5) 0–180.6 <0.001
a
3. Total overall charges 65.2 (80.6) 0–284.2 169.8 (195.0) 0–926.1 <0.001
a
Overall charges per year 23.0 (53.6) 0–298.1 141.5 (306.8) 0–1823.0 <0.001
a
Outpatient post-index 88 47
1. Total hospital charges 8.4 (4.9) 0–27.7 16.4 (40.3) 0–267.3 0.49
Hospital charges per year 1.3 (1.2) 0–7.5 4.4 (7.5) 0–34.3 <0.001
a
2. Physician charges 6.3 (3.6) 0–12.8 6.4 (6.1) 0–19.7 0.35
Physician charges per year 0.8 (0.5) 0–2.7 2.1 (2.6) 0–14.7 <0.001
a
3. Total overall charges 14.7 (7.6) 0–33.2 22.8 (44.0) 0–286.9 0.36
Overall charges per year 2.1 (1.5) 0–9.5 6.6 (9.6) 0–48.4 <0.001
a
Total post-index charges 88 79.9 (79.8) 0–302.0 47 192.6 (198.5) 11.2–958.4 <0.001
a
Total post-index charges per year 25.1 (54.0) 0–302.1 47 148.1 (308.4) 1.5–1824.0 <0.001
a
Grand total charges 88 150.4 (100.8) 41.4–682.5 47 263.6 (192.9) 27.5–982.8 <0.001
a
Grand total charges per year 39.2 (70.5) 2.6–374.5 47 216.7 (397.1) 8.0–1954.0 <0.001
a
After index admission, patients who died during index admission were excluded
EPCS emergency portacaval shunt, EST endoscopic sclerotherapy, PCS portacaval shunt
aStatistically significant difference
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ative measurements of both pressure and blood flow in
the portal vein in large numbers of patients have failed to
show a correlation between any hemodynamic measure-
ments performed prior to PCS and survival, hepatic
function, or development of PSE after PCS.
36–40 Our
studies of portal vein hemodynamics before PCS showed
no statistically significant correlation between pre-shunt
maximum perfusion pressure and post-shunt survival, liver
function, hepatic failure, or development of PSE.
38 It is
noteworthy that Burchell and colleagues in their extensive
intraoperative hemodynamic studies observed the largest
post-shunt increments in compensatory hepatic arterial flow
following side-to-side PCS, the procedure performed in 99 of
the 105 EPCS patients in our RCT. In the final analysis, the
long-term improvement in liver function following EPCS
observed inthe current trial provides the mostmeaningfuland
objective information regarding the effect of portal venous
flowdiversiononthecirrhoticliver.Eachyearfor5yearsafter
EPCS, liver function improved in 59–65% of patients, and
liver function declined in only 8–11%.
T h eS a nD i e g oB E VS t u d yp r o v i d e dau n i q u e
opportunity in a RCT to compare EPCS, a treatment
that is infrequently used today, with a conventional
treatment regimen consisting of rescue PCS following
failure of EST to control BEV. Not only did EPCS prove
to be superior to EST, but also, by every measure of
effectiveness, EPCS proved to be significantly better than
the combination of EST with rescue PCS. How can this
striking difference be explained? A likely explanation is
that patients who require rescue PCS are much more
severely ill than patients who undergo a diagnostic
workup and a definitive operation within 24 h of the
onset of bleeding. They are poorer candidates for
operation or, for that matter, for any other form of
rescue therapy. There is little doubt that persistent
variceal bleeding, repeated readmissions to the hospital,
and repeated bouts of PSE in the EST patients take their
toll. In point of fact, by the time rescue PCS was
required, many of the patients had experienced a decline
in liver function reflected by a negative change in
Child’s risk class. Furthermore, one third of the patients
who failed EST died before having the opportunity to
undergo rescue PCS, a common occurrence in programs
that treat cirrhotic patients with BEV.
Kahn et al.,
5 in their extensive review of emergency
treatment of BEV, identified serious shortcomings in many
of the reported studies. The San Diego BEV Study was
designed to overcome these shortcomings and was unique
in the following respects: (1) the 211 patients with acute
BEV were unselected and consecutive; (2) physicians
from four California counties with a population of 8.5
million agreed to participate in the study; (3) the
diagnostic workup was completed rapidly in a mean 3.1–
4.4 h, entirely at the bedside in the ICU; (4) unlike any
reported study to date, definitive treatment with EST or
EPCS was started within 8 h of study entry in 208 of 211
patients; (5) the surgeons and gastroenterologists were
experienced senior faculty physicians; (6) follow-up was
100%, was regular, and extended for 9.4 to more than
10 years or until death; (7) concerted, organized, and often
successful efforts were made to control dietary protein
intake and alcoholism; (8) PSE was determined and
prevented according to a clearly defined protocol by a
“blinded” senior gastroenterologist; and (9) consistent
with our past experience following EPCS, only 2 of 105
patients developed shunt occlusion, which prevented
recurrent BEV and PSE.
Conclusion
In this RCT of emergency treatment of acute BEV in 211
unselected, consecutive patients with cirrhosis of all grades of
severity,EPCSwasstrikingly superiortoESTaswellastothe
combination of ESTand rescue PCS in regard to all outcome
measures, specifically control of bleeding, survival, incidence
ofPSE,improvementinliverfunction,qualityoflife,andcost
of care. These results contradict the widespread belief that
PCS,otherwise knownastotal shunt,isassociatedwitha high
incidence of PSE and causes liver failure. Moreover, these
results call into question the widespread practice of relegating
PCS solely to salvage failure of endoscopic therapy of BEV
and strongly support the use of EPCS as the first line of
emergency treatment of BEV in cirrhosis.
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